SARS-CoV-2 evolution and evasion from multiple antibody treatments in a cancer patient

Guy Shapira, Chen Weiner, Reut Sorek Abramovich, Odit Gutwein, Nir Rainy, Patricia Benveniste-Levkovitz, Ezra Gordon, Adina Bar Chaim, Noam Shomron
doi: https://doi.org/10.1101/2022.06.25.22276445

Article Information

doi 
https://doi.org/10.1101/2022.06.25.22276445
History 
  • June 25, 2022.
Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.

Author Information

  1. Guy Shapira1,2,*,
  2. Chen Weiner1,3,
  3. Reut Sorek Abramovich3,
  4. Odit Gutwein4,
  5. Nir Rainy3,
  6. Patricia Benveniste-Levkovitz3,
  7. Ezra Gordon1,
  8. Adina Bar Chaim3 and
  9. Noam Shomron1,2
  1. 1Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
  2. 2Edmond J Safra Center for Bioinformatics, Tel Aviv University, Tel Aviv, Israel
  3. 3Shamir Medical Center, Shamir Medical Center (Assaf Harofeh), Zerifin, Israel
  4. 4Department of Hematology, Shamir Medical Center (Assaf Harofeh), Zerifin, Israel
  1. ↵* Corresponding author; email: guyshapira{at}mail.tau.ac.il
Back to top
Posted June 25, 2022.
Download PDF
Data/Code
Email
SARS-CoV-2 evolution and evasion from multiple antibody treatments in a cancer patient
Guy Shapira, Chen Weiner, Reut Sorek Abramovich, Odit Gutwein, Nir Rainy, Patricia Benveniste-Levkovitz, Ezra Gordon, Adina Bar Chaim, Noam Shomron
medRxiv 2022.06.25.22276445; doi: https://doi.org/10.1101/2022.06.25.22276445
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area